SIZE REDUCTION OF A PROLACTIN SECRETING ADENOMA DURING LONG‐TERM TREATMENT WITH THE DOPAMINE AGONIST LISURIDE
- 1 January 1980
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 12 (1) , 47-51
- https://doi.org/10.1111/j.1365-2265.1980.tb03131.x
Abstract
A 38–year‐old amenorrhoeic woman suffering from a prolactin (PRL) secreting adenoma, which had suprasellar extension as shown by carotid angiography and computed axial tomography (CAT), was treated with a dopamine agonist (lisuride). PRL levels were lowered and after 1 year of treatment CAT showed a marked reduction of the tumour size. After 2 years of treatment menstruation returned and CAT demonstrated a further reduction of the adenomatous tissue. This study supports the suggestion that dopamine agonists possess an anti‐pro‐liferative effect on tumoural lactotrophic cells of humans.This publication has 5 references indexed in Scilit:
- BROMOCRIPTINE IN PITUITARY TUMOURSThe Lancet, 1978
- Lisuride Hydrogen Maleate: Evidence for a Long Lasting Dopaminergic Activity in HumansJournal of Clinical Endocrinology & Metabolism, 1978
- Treatment of patients with prolactinomasJournal of Endocrinological Investigation, 1978
- Effect of the Ergot Derivative Lisuride Hydrogen Maleate on Serum Prolactin Concentrations in Female RatsEndocrinology, 1976
- Ergot-Induced Inhibition of Pituitary Tumor Growth in RatsScience, 1972